Curium Announces First Commercial Doses of PYLCLARI for Patients with Prostate Cancer in Poland
PYLCLARI® provides solutions to a wider patient group across Poland where there…
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
- First patient in the world treated with Alpha DaRT® in the…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L…
ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of…
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov.…
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable…
